- Home
- SNDX vs BASE Comparison
SNDX vs BASE Comparison
Compare SNDX & BASE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- BASE
- Stock Information
- Founded
- SNDX 2005
- BASE 2011
- Country
- SNDX United States
- BASE United States
- Employees
- SNDX N/A
- BASE N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- BASE EDP Services
- Sector
- SNDX Health Care
- BASE Technology
- Exchange
- SNDX Nasdaq
- BASE Nasdaq
- Market Cap
- SNDX 1.1B
- BASE 1.3B
- IPO Year
- SNDX 2016
- BASE 2021
- Fundamental
- Price
- SNDX $16.24
- BASE $24.37
- Analyst Decision
- SNDX Strong Buy
- BASE Hold
- Analyst Count
- SNDX 10
- BASE 16
- Target Price
- SNDX $37.50
- BASE $22.97
- AVG Volume (30 Days)
- SNDX 2.9M
- BASE 570.3K
- Earning Date
- SNDX 08-04-2025
- BASE 09-03-2025
- Dividend Yield
- SNDX N/A
- BASE N/A
- EPS Growth
- SNDX N/A
- BASE N/A
- EPS
- SNDX N/A
- BASE N/A
- Revenue
- SNDX $77,933,000.00
- BASE $214,662,000.00
- Revenue This Year
- SNDX $434.67
- BASE $12.42
- Revenue Next Year
- SNDX $108.62
- BASE $14.20
- P/E Ratio
- SNDX N/A
- BASE N/A
- Revenue Growth
- SNDX 2126.66
- BASE 12.76
- 52 Week Low
- SNDX $8.58
- BASE $12.78
- 52 Week High
- SNDX $22.50
- BASE $25.16
- Technical
- Relative Strength Index (RSI)
- SNDX 79.83
- BASE 67.87
- Support Level
- SNDX $15.36
- BASE $24.31
- Resistance Level
- SNDX $16.33
- BASE $24.41
- Average True Range (ATR)
- SNDX 0.78
- BASE 0.06
- MACD
- SNDX 0.31
- BASE -0.07
- Stochastic Oscillator
- SNDX 96.87
- BASE 68.42
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.